Lead Sponsor

AbbVie

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•US military veteran currently receiving healthcare through the Veterans Health Administration
•Screening laboratory result indicating hepatitis C virus (HCV), genotype 1-infection
•Positive for hepatitis C antibodies or HCV RNA at least 6 months before Screening, and HCV RNA \> 1,000 IU/mL at the time of Screening or HCV RNA \> 1,000 IU/mL at the time of Screening with a liver biopsy consistent with chronic HCV-infection (or a liver biopsy performed prior to enrollment with evidence of chronic hepatitis C disease)

•Women who are pregnant or breastfeeding
•Positive test result for hepatitis B surface antigen (HbsAg) or anti-HIV antibodies (HIV Ab)
•Prior or current use of any investigational or commercially available anti-HCV agents other than IFN, pegIFN, RBV or sofosbuvir
•Any current or past clinical evidence of Child-Pugh B or C classification
•Confirmed presence of hepatocellular carcinoma indicated on imaging techniques within 3 months prior to Screening or on an ultrasound performed at Screening for participants with cirrhosis

Related studies

NCT06345547 · Sarcopenia, Cirrhosis, and more

NCT07069725 · Liver Fibrosis, Hepatic Cirrhosis

NCT07439939 · Liver Cirrhosis, Portal Hypertension

NCT05623150 · Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis, and more

NCT05899231 · Cirrhosis, Liver, Liver Transplant Surgery, and more

A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in US Veterans With Genotype 1 Chronic Hepatitis C Virus Infection